Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice

被引：15

作者：

Fabi, Alessandra ^{[1
]}

Moscetti, Luca ^{[2
]}

Ciccarese, Mariangela ^{[3
]}

Caramanti, Miriam ^{[4
]}

Salesi, Nello ^{[5
]}

La Verde, Nicla ^{[6
]}

Russillo, Michelangelo ^{[7
]}

Generali, Daniele ^{[8
]}

Scandurra, Giuseppina ^{[9
]}

Vari, Sabrina ^{[1
]}

Pacetti, Umberto ^{[10
]}

Cognetti, Francesco ^{[1
]}

Giannarelli, Diana ^{[11
]}

机构：

[1] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy

[2] Bel Colle Hosp, Dept Med Oncol, Viterbo, Italy

[3] Fazi Hosp, Dept Med Oncol, Lecce, Italy

[4] Politecn Univ Marche, Ancona, Italy

[5] Dept Med Oncol, Latina, Italy

[6] Fatebenefratelli Hosp, Dept Med Oncol, Milan, Italy

[7] Campo di Marte Hosp, Dept Med Oncol, Lucca, Italy

[8] Ist Ospitalieri, Dept Med Oncol, Cremona, Italy

[9] Azienda Osped Emergenze Cannizzaro, Dept Med Oncol, Catania, Italy

[10] A Fiorini Hosp, Dept Med Oncol, Terracina, Italy

[11] Regina Elena Inst Canc Res, Biostat Unit, Rome, Italy

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 03期

关键词：

brain metastases; eribulin; metastatic breast cancer; triple negative; HALICHONDRIN B ANALOG; PHASE-II; BRAIN METASTASES; OPEN-LABEL; MESYLATE; ANTHRACYCLINE; CAPECITABINE; NEUROPATHY; REGRESSION; AGENTS;

D O I：

10.2217/fon.14.271

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: This multicenter study describes the effectiveness of eribulin in current practice. Patients & methods: In total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled. Results: The median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable. Conclusion: Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.

引用

页码：431 / 438

页数：8

共 22 条

[1]

[Anonymous], P AM ASS CANC RES

[2]

[Anonymous], J CLIN ONCOL S

[3] A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer [J].

Aogi, K. ;

Iwata, H. ;

Masuda, N. ;

Mukai, H. ;

Yoshida, M. ;

Rai, Y. ;

Taguchi, K. ;

Sasaki, Y. ;

Takashima, S. .

ANNALS OF ONCOLOGY, 2012, 23 (06) :1441-1448

[4] Peripheral Neuropathy with Microtubule-Targeting Agents: Occurrence and Management Approach [J].

Carlson, Karen ;

Ocean, Allyson J. .

CLINICAL BREAST CANCER, 2011, 11 (02) :73-81

[5] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].

Cortes, Javier ;

O'Shaughnessy, Joyce ;

Loesch, David ;

Blum, Joanne L. ;

Vahdat, Linda T. ;

Petrakova, Katarina ;

Chollet, Philippe ;

Manikas, Alexey ;

Dieras, Veronique ;

Delozier, Thierry ;

Vladimirov, Vladimir ;

Cardoso, Fatima ;

Koh, Han ;

Bougnoux, Philippe ;

Dutcus, Corina E. ;

Seegobin, Seth ;

Mir, Denis ;

Meneses, Nicole ;

Wanders, Jantien ;

Twelves, Chris .

LANCET, 2011, 377 (9769) :914-923

[6] Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine [J].

Cortes, Javier ;

Vahdat, Linda ;

Blum, Joanne L. ;

Twelves, Chris ;

Campone, Mario ;

Roche, Henri ;

Bachelot, Thomas ;

Awada, Ahmad ;

Paridaens, Robert ;

Goncalves, Anthony ;

Shuster, Dale E. ;

Wanders, Jantien ;

Fang, Fang ;

Gurnani, Renuka ;

Richmond, Elaine ;

Cole, Patricia E. ;

Ashworth, Simon ;

Allison, Mary Ann .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) :3922-3928

[7] Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: Another arrow at the bow? [J].

Fabi, A ;

Vidiri, A ;

Ferretti, G ;

Felici, A ;

Papaldo, P ;

Carlini, P ;

Mirri, A ;

Nuzzo, C ;

Cognetti, F .

CANCER INVESTIGATION, 2006, 24 (04) :466-468

[8] Approved Agents for Metastatic Breast Cancer [J].

Fornier, Monica N. .

SEMINARS IN ONCOLOGY, 2011, 38 (03) :S3-S10

[9] Treatment of breast cancer brain metastases [J].

Freedman R.A. ;

Anders C.K. .

Current Breast Cancer Reports, 2012, 4 (1) :1-9

[10] A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies [J].

Goel, Sanjay ;

Mita, Alain C. ;

Mita, Monica ;

Rowinsky, Eric K. ;

Chu, Quincy S. ;

Wong, Nancy ;

Desjardins, Christopher ;

Fang, Fang ;

Jansen, Mendel ;

Shuster, Dale E. ;

Mani, Sridhar ;

Takimoto, Chris H. .

CLINICAL CANCER RESEARCH, 2009, 15 (12) :4207-4212

← 1 2 3 →